The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

Many people believe that urinary tract infections (UTIs) and incontinence are more common in women, but they can also affect ...

The most commonly used medications to treat OAB have anticholinergic properties. Anticholinergics are competitive inhibitors of acetylcholine at muscarinic receptors (mainly the M3 receptor ...

With this tool, a fall-risk score is based on a patient's mental status, cognition, mobility, vision, history of falls, urinary urgency or incontinence, and medications. Patients receive points ...

In today’s fast-paced world, many women are turning a blind eye to a common yet often unspoken issue: urinary incontinence.

The researchers found that Er-YAG laser vaginal treatment was not more effective than the sham procedure in curing or ...

Understanding available treatment options helps individuals make informed decisions about their health care needs. Urinary incontinence, commonly known as bladder control issues, ranges from mild ...

Driven by a combination of demographic, social, and technological factors, the disposable incontinence products industry is ...